Educational guide
Boehringer Ingelheim to Acquire Actimis Pharmaceuticals for $515M
Innovative buyout structured around success of Actimis’ leading asthma compound. Boehringer Ingelheim will acquire Actimis Pharmaceuticals through a structured buyout in which Boehringer Ingelheim will acquire shares of Actimis depending on the achievement of
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Innovative buyout structured around success of Actimis’ leading asthma compound.
Boehringer Ingelheim will acquire Actimis Pharmaceuticals through a structured buyout in which Boehringer Ingelheim will acquire shares of Actimis depending on the achievement of several successive milestones with Actimis’ leading asthma compound AP768. If AP768, currently in Phase I development, is successfully advanced into a Phase III, Boehringer Ingelheim will own 100% of Actimis’ shares. Upon successful completion of the entire development program, the total deal will be worth $515 million. AP768 interacts with CRTH21, a target for asthma and allergic rhinitis. Previous to the currently ongoing Phase I trial, the compound was shown to have a more effective mechanism of action across multiple available animal models compared to currently marketed leukotriene receptor antagonists, according to the companies.
Related Links:
Researchers Discover SNP Linked to Asthma
Using Multi-Pathway Target Knockdown
Managing Asthma and COPD Treatments